Immuno-Biological Laboratories Co., Ltd.

Tokyo Stock Exchange 4570.T

Immuno-Biological Laboratories Co., Ltd. Net Income Margin for the year ending March 31, 2024: 22.86%

Immuno-Biological Laboratories Co., Ltd. Net Income Margin is 22.86% for the year ending March 31, 2024, a 162.69% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Immuno-Biological Laboratories Co., Ltd. Net Income Margin for the year ending March 31, 2023 was -36.46%, a 8.75% change year over year.
  • Immuno-Biological Laboratories Co., Ltd. Net Income Margin for the year ending March 31, 2022 was -39.96%, a 24.46% change year over year.
  • Immuno-Biological Laboratories Co., Ltd. Net Income Margin for the year ending March 31, 2021 was -52.90%, a 54.39% change year over year.
  • Immuno-Biological Laboratories Co., Ltd. Net Income Margin for the year ending March 31, 2020 was -115.97%.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
Loading...
Tokyo Stock Exchange: 4570.T

Immuno-Biological Laboratories Co., Ltd.

CEO Tsutomu Seito
IPO Date Aug. 15, 2007
Location Japan
Headquarters Fujioka Laboratory
Employees 57
Sector Health Care
Industries
Description

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email